The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics

Cancer Causes and Control

Volumn 26, Issue 10, 2015, Pages 1405-1419

  Samavat, Hamed ^a   Dostal, Allison M ^a   Wang, Renwei ^b   Bedell, Sarah ^a   Emory, Tim H ^c   Ursin, Giske ^d,e,f   Torkelson, Carolyn J ^c   Gross, Myron D ^c   Le, Chap T ^g,h   Yu, Mimi C ^f   Yang, Chung S ⁱ   Yee, Douglas ^a,c,h   Wu, Anna H ^f   Yuan, Jian Min ^b,j   Kurzer, Mindy S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d CANCER REGISTRY OF NORWAY   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ RUTGERS UNIVERSITY   (United States)

^j UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Breast cancer; Green tea; Mammographic density; Postmenopausal women; Sex hormones

Indexed keywords

ALANINE AMINOTRANSFERASE; ANDROSTENEDIONE; CATECHOL METHYLTRANSFERASE; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; ESTRADIOL; ESTRONE; GREEN TEA EXTRACT; ISOPROSTANE DERIVATIVE; PLACEBO; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; TUMOR MARKER; ANTIOXIDANT; BIOLOGICAL MARKER; CATECHIN; ESTROGEN; SEX HORMONE; TEA;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DENSITY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIGITAL MAMMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ANALOGS AND DERIVATIVES; ANATOMY AND HISTOLOGY; BLOOD; BREAST; BREAST NEOPLASMS; GENETICS; MAMMOGRAPHY; METABOLISM; MIDDLE AGED; MINNESOTA; OXIDATIVE STRESS; RISK FACTOR; TEA; URINE;

ANTIOXIDANTS; BIOMARKERS; BREAST; BREAST NEOPLASMS; CATECHIN; CATECHOL O-METHYLTRANSFERASE; DOUBLE-BLIND METHOD; ESTROGENS; F2-ISOPROSTANES; FEMALE; GENOTYPE; GONADAL STEROID HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAMMOGRAPHY; MIDDLE AGED; MINNESOTA; OXIDATIVE STRESS; RISK FACTORS; TEA;

EID: 84941415908     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0632-2     Document Type: Article

References (43)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29
2. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T et al (2012) American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 62:30–67
3. Thomson CA (2012) Diet and breast cancer: understanding risks and benefits. Nutr Clin Pract 27:636–650
4. Yang CS, Wang X, Lu G, Picinich SC (2009) Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 9:429–439
5. Wang ZY, Huang MT, Lou YR, Xie JG, Reuhl KR, Newmark HL, Ho CT, Yang CS, Conney AH (1994) Inhibitory effects of black tea, green tea, decaffeinated black tea, and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7,12-dimethylbenz[a]anthracene-initiated SKH-1 mice. Cancer Res 54:3428–3435
6. Sartippour MR, Shao ZM, Heber D, Beatty P, Zhang L, Liu C, Ellis L, Liu W, Go VL, Brooks MN (2002) Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr 132:2307–2311
7. Ogunleye AA, Xue F, Michels KB (2010) Green tea consumption and breast cancer risk or recurrence: a meta-analysis. Breast Cancer Res Treat 119:477–484
8. Yang CS, Wang H, Li GX, Yang Z, Guan F, Jin H (2011) Cancer prevention by tea: evidence from laboratory studies. Pharmacol Res 64:113–122
9. Wu AH, Ursin G, Koh WP, Wang R, Yuan JM, Khoo KS, Yu MC (2008) Green tea, soy, and mammographic density in Singapore Chinese women. Cancer Epidemiol Biomarkers Prev 17:3358–3365
10. Wu AH, Arakawa K, Stanczyk FZ, Van Den Berg D, Koh WP, Yu MC (2005) Tea and circulating estrogen levels in postmenopausal Chinese women in Singapore. Carcinogenesis 26:976–980
11. Fuhrman BJ, Pfeiffer RM, Wu AH, Xu X, Keefer LK, Veenstra TD, Ziegler RG (2013) Green tea intake is associated with urinary estrogen profiles in Japanese-American women. Nutr J 12:25
12. Li M, He Z, Ermakova S, Zheng D, Tang F, Cho YY, Zhu F, Ma WY, Sham Y, Rogozin EA et al (2007) Direct inhibition of insulin-like growth factor-I receptor kinase activity by (–)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev 16:598–605
13. Yang CS, Maliakal P, Meng X (2002) Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 42:25–54
14. Klaunig JE, Kamendulis LM (2004) The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44:239–267
15. Donovan JL, DeVane CL, Chavin KD, Oates JC, Njoku C, Patrick KS, Fiorini RN, Markowitz JS (2005) Oral administration of a decaffeinated green tea (Camellia sinensis) extract did not alter urinary 8-epi-prostaglandin F(2 alpha), a biomarker for in vivo lipid peroxidation. J Pharm Pharmacol 57:1365–1369
16. Qian G, Xue K, Tang L, Wang F, Song X, Chyu MC, Pence BC, Shen CL, Wang JS (2012) Mitigation of oxidative damage by green tea polyphenols and Tai Chi exercise in postmenopausal women with osteopenia. PLoS ONE 7:e48090
17. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996) Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243–250
18. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF (2001) Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 61:6716–6722
19. Inoue-Choi M, Yuan JM, Yang CS, Van Den Berg DJ, Lee MJ, Gao YT, Yu MC (2010) Genetic association between the COMT genotype and urinary levels of tea polyphenols and their metabolites among daily green tea drinkers. Int J Mol Epidemiol Genet 1:114–123
20. Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27:135–206
21. Wu AH, Tseng CC, Van Den Berg D, Yu MC (2003) Tea intake, COMT genotype, and breast cancer in Asian-American women. Cancer Res 63:7526–7529
22. ® Atlas)-mammography, 4th edn. American College of Radiology, Reston, VA, pp 179–180
23. Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, Guyatt GH, Norton PG, Dunn E (1996) A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 24:161–175
24. Lewis JE, Hilditch JR, Wong CJ (2005) Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version. MENQOL-Intervention questionnaire. Maturitas 50:209–221
25. Bhagwat S, Haytowitz DB, Holden JM (2014) USDA Database for the flavonoid content of selected foods, release 3.1. U.S. Department of Agriculture, Agricultural Research Service. Nutrient Data Laboratory Home Page: http://www.ars.usda.gov/nutrientdata/flav. Accessed 13 Dec 2014
26. Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV (1998) The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 7:43–47
27. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC (2003) Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 12:332–338
28. Salameh WA, Redor-Goldman MM, Clarke NJ, Reitz RE, Caulfield MP (2010) Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: total and free testosterone reference ranges. Steroids 75:169–175
29. Xu X, Veenstra TD, Fox SD, Roman JM, Issaq HJ, Falk R, Saavedra JE, Keefer LK, Ziegler RG (2005) Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 77:6646–6654
30. Morrow JD, Chen Y, Brame CJ, Yang J, Sanchez SC, Xu J, Zackert WE, Awad JA, Roberts LJ (1999) The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metab Rev 31:117–139
31. Morrow JD (2000) The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 32:377–385
32. Morrow JD, Roberts LJ (2002) Mass spectrometric quantification of F2-isoprostanes as indicators of oxidant stress. Methods Mol Biol 186:57–66
33. Gross M, Steffes M, Jacobs DR, Yu X, Lewis L, Lewis CE, Loria CM (2005) Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin Chem 51:125–131
34. Lee MJ, Prabhu S, Meng X, Li C, Yang CS (2000) An improved method for the determination of green and black tea polyphenols in biomatrices by high-performance liquid chromatography with coulometric array detection. Anal Biochem 279:164–169
35. Li C, Lee MJ, Sheng S, Meng X, Prabhu S, Winnik B, Huang B, Chung JY, Yan S, Ho CT et al (2000) Structural identification of two metabolites of catechins and their kinetics in human urine and blood after tea ingestion. Chem Res Toxicol 13:177–184
36. Slot C (1965) Plasma creatinine determination. A new and specific Jaffe reaction method. Scand J Clin Lab Invest 17:381–387
37. Hong CC, Thompson HJ, Jiang C, Hammond GL, Tritchler D, Yaffe M, Boyd NF (2003) Val158Met Polymorphism in catechol-O-methyltransferase gene associated with risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 12:838–847
38. Wu AH, Spicer D, Stanczyk FZ, Tseng CC, Yang CS, Pike MC (2012) Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women. Cancer Prev Res (Phila) 5:393–402
39. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L et al (2012) Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) 5:1144–1154
40. Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, Crowell JA, Yang CS, Hara Y (2001) Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10:53–58
41. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS (2003) Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9:3312–3319
42. Dostal AM, Samavat H, Bedell S, Torkelson C, Wang R, Swenson K, Le C, Wu AH, Ursin G, Yuan JM et al (2015) The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial. Food Chem Toxicol 83:26–35
43. Neveu V, Perez-Jiménez J, Vos F, Crespy V, du Chaffaut L, Mennen L, Knox C, Eisner R, Cruz J, Wishart D et al (2010) Phenol-explorer: an online comprehensive database on polyphenol contents in foods. Database (Oxford) 2010, bap024